AI-driven dermatology platform Cureskin has netted $20 million in a Series B funding round led by HealthQuad. The round was also participated by JSW Ventures, Khosla Ventures, and Sharrp Ventures.
“These funds will help further enhance our AI capabilities, accelerate our growth, and expand solution offerings,” said co-founder and CEO Guna Kakulapati in a statement.
Cureskin previously raised $5 million in Series A funding. To date, it claims to have treated about 1.5 million customers for various skin conditions through its app. It notes that over 80% of them are from tier 2 and 3 cities.
Diabetes-focused health tech startup Sugar.fit has received an additional $5 million in Series A funding from B Capital.
This brings its total Series A funding, the first round of which occurred in November, to $16 million.
In a statement, the company said it will use its additional funds to expand its offerings, increase its presence, and hasten R&D in diabetes management.
Since launching by end-2021, Sugar.fit has now served over 30,000 users on its platform, offering a personalised, comprehensive program for managing diabetes that leverages continuous glucose monitoring technology and data. It has also recently started operating diabetes clinics in Bangalore, which offer a range of services such as stress therapies, live fitness and yoga sessions, and VR chromotherapy.
Diagnostic service provider Cardiotrack, a brand of Uber Diagnostics, has obtained $2 million in a pre-Series A funding round led by Girish Narasimhan, angel investor and principal of an international investment banking firm.
This adds to the $1.6 million it raised previously from a cohort of high-net-worth individuals. It has not disclosed where and how it will use its fresh funds.
Cardiotrack, which offers telemedicine kits, medical-grade and IoT diagnostic devices, and data analytics solutions, serves some of India’s largest health and life insurers and network of diagnostic centres in over 300 locations.
